secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0001140361-22-025657
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva to acquire La Jolla Pharmaceutical for $6.23/share in cash, ~$149M EV
------------------------------------------------------------------------------

- Offer price $6.23/share ($5.95 base + $0.28 from non-core asset sale); 70% premium to 30-day VWAP.
- Implied enterprise value approximately $149 million; tender offer expected within ~30 business days.
- Adds GIAPREZA (angiotensin II) and XERAVA (eravacycline) to Innoviva's infectious disease portfolio.
- Stockholders holding ~40% of La Jolla shares signed support agreement to tender shares.
- Transaction unanimously approved by both boards; subject to majority tender and other customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/0001140361-22-025657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-025657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer